PCI, a Philadelphia, Pa.-based global service provider, has acquired Biotec Services International. Biotec is a provider of clinical trial services and temperature controlled pharmaceutical services headquartered in Bridgend, Wales in the U.K. The addition significantly expands PCI's presence in the E.U. to support global investigational studies of medicinal products by adding packaging, storage and distribution capacity, as well as consultative services for clinical trial supplies.
Biotec recently has undertaken a facilities expansion to accommodate additional packaging, storage and distribution demand. Biotec's experience supports global projects across a range of temperature conditions including controlled room temperature, 2 - 8°C, -20°C, -40°C, -80°C and specialization in products requiring -196°C.
Biotec's expansion more than quadruples PCI’s capacity to store, package and ship cold chain products, and includes a second purpose built facility for the storage of advanced therapeutic medicinal products (ATMP) at -196°C.
PCI recently acquired Penn Pharma, adding pharmaceutical development and contained manufacturing services to its portfolio of clinical trial services, commercial packaging and laboratory services. The addition of Penn Pharma follows PCI's acquisition of AndersonBrecon in 2013 from AmerisourceBergen. PCI now represents 16 facilities across North America and Europe, employing over 2,900 associates.
Fiona Withey, CEO of Biotec Services, said, "In a recent client survey, our clients told us that we should continue to do what we are doing, but should aim to develop the scope and global presence of our offering. Joining the PCI family allows us to deliver a truly global service to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility."